Logo image of GNRO.PA

GENEURO SA (GNRO.PA) Stock Fundamental Analysis

Europe - EPA:GNRO - CH0308403085 - Common Stock

0.041 EUR
+0.01 (+13.89%)
Last: 11/10/2025, 11:45:28 AM
Fundamental Rating

0

GNRO gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 74 industry peers in the Biotechnology industry. GNRO may be in some trouble as it scores bad on both profitability and health. GNRO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

GNRO had negative earnings in the past year.
In the past year GNRO has reported a negative cash flow from operations.
In the past 5 years GNRO always reported negative net income.
GNRO had a negative operating cash flow in each of the past 5 years.
GNRO.PA Yearly Net Income VS EBIT VS OCF VS FCFGNRO.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5M -5M 10M -10M -15M

1.2 Ratios

With a Return On Assets value of -231.93%, GNRO is not doing good in the industry: 94.59% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -231.93%
ROE N/A
ROIC N/A
ROA(3y)-130.9%
ROA(5y)-115.72%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GNRO.PA Yearly ROA, ROE, ROICGNRO.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K -8K

1.3 Margins

GNRO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GNRO.PA Yearly Profit, Operating, Gross MarginsGNRO.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150 -200

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, GNRO has about the same amount of shares outstanding.
Compared to 5 years ago, GNRO has more shares outstanding
The debt/assets ratio for GNRO is higher compared to a year ago.
GNRO.PA Yearly Shares OutstandingGNRO.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M
GNRO.PA Yearly Total Debt VS Total AssetsGNRO.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

2.2 Solvency

GNRO has an Altman-Z score of -20.69. This is a bad value and indicates that GNRO is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -20.69, GNRO is doing worse than 83.78% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -20.69
ROIC/WACCN/A
WACCN/A
GNRO.PA Yearly LT Debt VS Equity VS FCFGNRO.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M

2.3 Liquidity

GNRO has a Current Ratio of 0.37. This is a bad value and indicates that GNRO is not financially healthy enough and could expect problems in meeting its short term obligations.
GNRO's Current ratio of 0.37 is on the low side compared to the rest of the industry. GNRO is outperformed by 89.19% of its industry peers.
GNRO has a Quick Ratio of 0.37. This is a bad value and indicates that GNRO is not financially healthy enough and could expect problems in meeting its short term obligations.
GNRO has a worse Quick ratio (0.37) than 87.84% of its industry peers.
Industry RankSector Rank
Current Ratio 0.37
Quick Ratio 0.37
GNRO.PA Yearly Current Assets VS Current LiabilitesGNRO.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

More info and screens

0

3. Growth

3.1 Past

GNRO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -17.24%.
EPS 1Y (TTM)-17.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.27%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-28.12%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GNRO.PA Yearly Revenue VS EstimatesGNRO.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2023 5M 10M 15M 20M
GNRO.PA Yearly EPS VS EstimatesGNRO.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

GNRO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year GNRO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GNRO.PA Price Earnings VS Forward Price EarningsGNRO.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GNRO.PA Per share dataGNRO.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.1 -0.2 -0.3 -0.4 -0.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

GNRO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GENEURO SA

EPA:GNRO (11/10/2025, 11:45:28 AM)

0.041

+0.01 (+13.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-25 2024-07-25
Earnings (Next)N/A N/A
Inst Owners17.06%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.22M
Revenue(TTM)N/A
Net Income(TTM)-14.75M
Analysts85.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.6
EYN/A
EPS(NY)-0.42
Fwd EYN/A
FCF(TTM)-0.34
FCFYN/A
OCF(TTM)-0.34
OCFYN/A
SpS0
BVpS-0.46
TBVpS-0.5
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -231.93%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-130.9%
ROA(5y)-115.72%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 8.51%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.37
Quick Ratio 0.37
Altman-Z -20.69
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)14.31%
Cap/Depr(5y)12.72%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-17.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.27%
EPS Next Y-28.12%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-27.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-30.49%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y22.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y22.31%
OCF growth 3YN/A
OCF growth 5YN/A

GENEURO SA / GNRO.PA FAQ

What is the fundamental rating for GNRO stock?

ChartMill assigns a fundamental rating of 0 / 10 to GNRO.PA.


Can you provide the valuation status for GENEURO SA?

ChartMill assigns a valuation rating of 0 / 10 to GENEURO SA (GNRO.PA). This can be considered as Overvalued.


How profitable is GENEURO SA (GNRO.PA) stock?

GENEURO SA (GNRO.PA) has a profitability rating of 0 / 10.


What is the earnings growth outlook for GENEURO SA?

The Earnings per Share (EPS) of GENEURO SA (GNRO.PA) is expected to decline by -28.12% in the next year.